- Home
- XBIT vs ALEC Comparison
XBIT vs ALEC Comparison
Compare XBIT & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBIT
- ALEC
- Stock Information
- Founded
- XBIT 2005
- ALEC 2013
- Country
- XBIT United States
- ALEC United States
- Employees
- XBIT N/A
- ALEC N/A
- Industry
- XBIT Pharmaceuticals and Biotechnology
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- XBIT Health Care
- ALEC Health Care
- Exchange
- XBIT Nasdaq
- ALEC Nasdaq
- Market Cap
- XBIT 105.2M
- ALEC 124.0M
- IPO Year
- XBIT 2015
- ALEC 2019
- Fundamental
- Price
- XBIT $2.85
- ALEC $1.33
- Analyst Decision
- XBIT
- ALEC Buy
- Analyst Count
- XBIT 0
- ALEC 7
- Target Price
- XBIT N/A
- ALEC $4.70
- AVG Volume (30 Days)
- XBIT 47.1K
- ALEC 1.2M
- Earning Date
- XBIT 05-14-2025
- ALEC 05-08-2025
- Dividend Yield
- XBIT N/A
- ALEC N/A
- EPS Growth
- XBIT N/A
- ALEC N/A
- EPS
- XBIT N/A
- ALEC N/A
- Revenue
- XBIT N/A
- ALEC $88,339,000.00
- Revenue This Year
- XBIT N/A
- ALEC N/A
- Revenue Next Year
- XBIT N/A
- ALEC $392.45
- P/E Ratio
- XBIT N/A
- ALEC N/A
- Revenue Growth
- XBIT N/A
- ALEC N/A
- 52 Week Low
- XBIT $2.65
- ALEC $0.87
- 52 Week High
- XBIT $8.32
- ALEC $6.78
- Technical
- Relative Strength Index (RSI)
- XBIT 45.38
- ALEC 55.51
- Support Level
- XBIT $2.71
- ALEC $1.01
- Resistance Level
- XBIT $2.98
- ALEC $1.46
- Average True Range (ATR)
- XBIT 0.13
- ALEC 0.12
- MACD
- XBIT 0.00
- ALEC 0.02
- Stochastic Oscillator
- XBIT 23.81
- ALEC 71.11
About XBIT XBiotech Inc.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.